

# Meeting the Challenge of the Next Epidemic/ Pandemic

**Neren Rau**

**December 2022**

# What the World needs ....

.... diversified vaccine manufacturing to sustainably supply vaccines through inter epi-/pandemic periods, particularly in under-served regions ...

- ✓ Agility to meet surge demands
- ✓ Robust supply chains that can produce in a crisis
- ✓ Worldwide availability of raw materials
- ✓ Platform/ innovative technologies
- ✓ Suitable and sustainable business models
- ✓ Trained/ skilled workforce around the world




# CEPI: A global partnership

## Vision

A world in which epidemics and pandemics are no longer a threat to humanity

## Mission

Accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need




CEPI


# CEPI funds vaccines, enabling science and Cross-cutting projects at a global scale...

CEPI's portfolio  
comprises:  
70+ partnerships,  
250+ awardees, in  
50 countries, across  
vaccine development,  
enabling science and  
cross-cutting activities

Equitable access is at  
the core of all CEPI  
agreements




# CEPI's vaccine portfolio



MERS

5 vaccine  
candidates




Lassa

6 vaccine  
candidates




Nipah

4 vaccine  
candidates



Chikungunya

3 vaccine  
candidates




Rift Valley  
fever

2 vaccine  
candidates




COVID-19

14 vaccine  
candidates –  
11 still in  
development



Disease X

3 platform  
technologies



Broadly protective  
SARS-CoV-2

4 vaccine  
candidates

CEPI

# CEPI response to COVID-19



Developing  
the world's  
largest  
vaccine  
portfolio



Investing at-  
risk to  
accelerate &  
expand  
manufacturing



Funding  
enabling  
science to  
support  
vaccine  
development



Strengthening  
our defences  
through  
additional  
R&D and  
broadly  
protective  
vaccines



Facilitating  
supply chain  
by securing  
raw materials  
and COVAX  
Marketplace



Enabling equitable access through COVAX



# Access lies at the heart of our plan



CEPI wants to give the world a fighting chance of tackling and containing outbreaks, before they spread and become pandemics.

But that only works if the vaccines are deployed in the country or region affected by the outbreak – regardless of where that may be.

That requires a fundamental shift in international collaboration and cooperation towards a system founded on the principle of equitable access.

# Access lies at the heart of our plan

## R&D

- ✓ Embedding EA requirements in CEPI R&D investments
- ✓ Assess vax demand (outbreak and endemic) as target for R&D and preparedness

## Manufacturing


- ✓ Geo-diversify manufacturing (tech transfers) and support capacity in LMICs
- ✓ Drive down costs of production through innovation and contractual arrangements

## Development Innovation

- ✓ Require data sharing, public disclosure, sharing of project materials
- ✓ Prioritise research on product profiles suited to LMICs



# ACT Accelerator




# Why COVAX matters

---




**Supporting countries to meet their vaccination goals**



**Globally fair distribution of vaccines**




**Diverse & actively managed portfolio of vaccines increases chances of success**



**Sharing the risks and benefits of vaccine R&D**



**Ending the acute phase of the pandemic**



**Rebuilding livelihoods and economies**

**~3bn doses of vaccine that have received R&D support from CEPI have been secured by COVAX.**

**Over 1bn doses have been delivered to 144 countries.**

# COVAX

---


CEPI



---

ACTaccelerator  
ACCESS TO COVID-19 TOOLS

# The COVAX Facility has 188 donors and confirmed participants



\*To note only 88 of the 92 eligible AMC territories are currently members of COVAX

To address immediate C-19 vaccine supply needs, a COVAX Marketplace was developed

CEPI runs the marketplace matching existing consumable supplies with vaccine manufacturing needs (since July 2021)

CEPI

## Facilitate production of C-19 Vx doses, promote equitable access

---

### Objectives

Platform to improve utilization of scarce consumable supplies by:




- Providing suppliers with a platform to (re-)allocate materials and capacity which become available through sudden shifts in demand
  - Mobilizing idle stock from vaccines (candidates) that fail prior to gaining regulatory approval
  - Mobilizing surplus stock from manufacturers with non-Vx activities
-

# Themes from completed/ ongoing evaluations



Varying commentary around the level of ambition of COVAX



LMICs and CSOs should have had greater engagement and ownership in design



Governance and decision-making complex and partner responsibilities sometimes unclear



COVAX results are recognized although all targets not reached



CEPI

Agencies and the global community should build on C-19 experience to strengthen future pandemic and emergency preparedness


- Support countries achieve full vax
- Protect high-risk populations (LMICs)
- Support complete vax of adults/adolescents
- Consider vax for 5-12 yrs (on request)
- Support 34 countries in finance + delivery
- Integrate C-19 vax into PHC interventions
- Support R&D, regulatory, policy, manufg
- Support COVAX to procure/ deploy new vax

## **COVAX OBJECTIVES 2022**



# What can we do differently?

- ❖ Prepare for a range of possibilities: emergency actions, invest for what's next, integrate SCs
- ❖ Reassess strategies: testing, diagnostics, therapeutics, non- pharma interventions
  - ❑ Conducive policy and infrastructure to enable innovation
  - ❑ Collaborate: surveillance, data sharing, tech and skills development, trade policy, hubs, surge financing
    - Geo-diversification and EA
    - Support the work of CEPI



Viruses like C-19 are not disappearing  
They are adapting!

We must invest **today**, to save tomorrow